Tests a heart stent in people who take blood thinners for coronary artery disease
Observes a sirolimus-eluting heart stent in adults on long-term oral anticoagulation.
Plain-language title generated from the registry record
Registry title: Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation
Key facts
- Where
- Albacete, Alicante, Badajoz, Castelló, Ciudad Real, Elche, L'Hospitalet de Llobregat, Laguna, Las Palmas de Gran Canaria, Majadahonda, Pamplona, Puerto del Rosario, and Zaragoza, SpainSee the 13 sites
Where in Spain
- Hospital General Universitario de AlbaceteAlbacete, SpainTaking people
- Hospital Universitario San Juan de AlicanteAlicante, SpainTaking people
- Hospital General Universitario de MeridaBadajoz, SpainTaking people
- Hospital General Universitari de CastellóCastelló, SpainTaking people
- H.G.U. de Ciudad Real.Ciudad Real, SpainTaking people
- Hospital General Universitari d'ElxElche, SpainTaking people
- Hospital Universitari de BellvitgeL'Hospitalet de Llobregat, SpainTaking people
- Hospital Universitario de CanariasLaguna, SpainTaking people
- Hospital Doctor Jose Molina OrosaLas Palmas de Gran Canaria, SpainTaking people
- Hospital Universitario Puerta de HierroMajadahonda, SpainTaking people
- Hospital Universitario de NavarraPamplona, SpainTaking people
- Hospital General de FuerteventuraPuerto del Rosario, SpainTaking people
- Hospital Clinico Universitario Lozano BlesaZaragoza, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundación EPIC
- Trial code
- NCT06863155
- Record updated
- 6 August 2026
- Original description
Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.Read full original descriptionShow less
Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation
Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.
Inclusion: Patients must meet all inclusion criteria:; Patients with Signed informed consent and; Patients with >=18 years old and; Patients with chronically receiving oral anticoagulation treatment with any type of anticoagulant for any reason and; Patients with de novo Coronary artery disease requiring both elective or urgent percutaneous revascularization due to stable coronary artery disease or acute coronary syndrome with or without ST-segment elevation, and in which an ultrathin strut Sirolimus-eluting stent with bioabsorbable polymer has been used.
Exclusion: Patients treated percutaneously with any type of stent other than the SupraFlex Cruz® in the 6 months prior to the index procedure in which he or she is included; Patients treatment for restenosis or stent thrombosis; Patients with allergy to any of the components of the stent to be used; Patients do not have to meet any exclusion criteria; Use in the same procedure or in a scheduled procedure of other stents different from the one evaluated for the treatment of another vessel(s); Patients presentation in cardiogenic shock or after cardiorespiratory arrest; Patients with impossibility for follow-up; Patients with life expectancy less than 1 year.